Abstract: Disclosed are antigen binding polypeptides and antigen binding polypeptide complexes (e.g., antibodies and antigen binding fragments thereof) having certain structural and/or functional features. Also disclosed are polynucleotides and vectors encoding such polypeptides and polypeptide complexes; host cells, pharmaceutical compositions and kits containing such polypeptides and polypeptide complexes; and methods of using such polypeptides and polypeptide complexes.

Abstract: An antitumor pharmaceutical composition and an application thereof. Active ingredients of the antitumor pharmaceutical composition contain a polyethylene glycol-modified camptothecin derivative (in particular, polyethylene glycol-modified irinotecan) and temozolomide. It is proved by means of animal experiments that the administration of polyethylene glycol-modified camptothecin derivative (in particular, polyethylene glycol-modified irinotecan) and temozolomide in combination has an extremely strong treatment effect on tumors (such as neuroblastoma), and the tumor inhibition rate can reach 98% and is significantly superior to that of a monotherapy group; thus, the provided antitumor pharmaceutical composition has better application prospects for treatment of tumors.

Abstract: A radiomic biomarker determination method and system for assessment of the risk of metabolic diseases. The method includes: obtaining abdominal & pelvic volumetric computed tomography (CT) scan from the given subject; determining the fat area to be analyzed from the CT scan, separating visceral fat using an image segmentation method, and normalizing the visceral fat area under physical scale; extracting N imaging features of the visceral fat; selecting n optimal imaging features from the N candidate features; dividing the normalized visceral fat area into multiple visceral fat blocks with equal thickness; extracting n corresponding optimal imaging features from each visceral fat block, named as block imaging features; and determining the representative visceral fat block from the candidate blocks and taking the representative visceral fat block and the (block) imaging features extracted from the representative visceral fat block as radiomic biomarkers.

Abstract: Disclosed is a pair of specific primers for identifying Asian gypsy moth and a method of detection thereby. In the present disclosure, based on the SS-COI technology, primers for distinguishing other species of Lymantria are designed according to the specific region of the mitochondrial COI gene of Asian gypsy moth. The pair of primers has accurate identification effects on different geographical populations, different insect states and different instars of Asian gypsy moth; in addition, the whole detection process only takes 2-3 hours, which has the advantages of rapidity and accuracy.

Abstract: The invention discloses use of a conjugate of polyethylene glycol and a local anesthetic in non-anesthetic analgesia. A local anesthetic is prepared into a prodrug or a sustained release preparation, wherein a high molecular polymer such as polyethylene glycol in the prodrug is covalently bonded with a local anesthetic, and auxiliary materials with a sustained release effect in the sustained release preparation are non-covalently bonded to the local anesthetic. After administration, there is no anesthesia and analgesic effect before the release of the free local anesthetic. After the free local anesthetic is released, an analgesic effect is achieved.

Abstract: The invention discloses use of a conjugate of polyethylene glycol and a local anesthetic in non-anesthetic analgesia. A local anesthetic is prepared into a prodrug or a sustained release preparation, wherein a high molecular polymer such as polyethylene glycol in the prodrug is covalently bonded with a local anesthetic, and auxiliary materials with a sustained release effect in the sustained release preparation are non-covalently bonded to the local anesthetic. After administration, there is no anesthesia and analgesic effect before the release of the free local anesthetic. After the free local anesthetic is released, an analgesic effect is achieved.

Abstract: According to one embodiment, a controller writes either processed data or preprocessing data and flags into each page included in m pages. The processed data is data after first data translation of write data to be written into a relevant page. The preprocessing data is data before the first data translation of the write data to be written into the relevant page. Each of the flag at least represents whether or not the first data translation is performed for write data to be written into the relevant page.

Abstract: According to one embodiment, a controller writes first processed data acquired by a first process into a nonvolatile memory during a first period. The controller writes second processed data acquired by a second process into the nonvolatile memory during a second period. The first process is for the purpose of improving the endurance of memory cells. The second process is for the purpose of decreasing inter-cell interferences between adjacent cells.

Abstract: According to one embodiment, a controller writes first processed data acquired by a first process into a nonvolatile memory during a first period. The controller writes second processed data acquired by a second process into the nonvolatile memory during a second period. The first process is for the purpose of improving the endurance of memory cells. The second process is for the purpose of decreasing inter-cell interferences between adjacent cells.

Abstract: According to one embodiment, a memory system includes a non-volatile memory, a memory interface that performs programming and reading out with respect to the non-volatile memory, a code processor that generates a code word by encoding; and a controller that sets a threshold-voltage read level for determining whether a value of each bit in a received word read out from the non-volatile memory is “0” or “1”. A difference between the number of bits which have value equals “0” and the number of bits which have value equals “1” in the code word depends on a code rate of the encoding. The controller obtains the threshold-voltage read level based on the code rate.

Abstract: According to one embodiment, a controller writes either processed data or preprocessing data and flags into each page included in m pages. The processed data is data after first data translation of write data to be written into a relevant page. The preprocessing data is data before the first data translation of the write data to be written into the relevant page. Each of the flag at least represents whether or not the first data translation is performed for write data to be written into the relevant page.

Abstract: According to one embodiment, a memory system includes a non-volatile memory, a memory interface that performs programming and reading out with respect to the non -volatile memory, a code processor that generates a code word by encoding; and a controller that sets a threshold -voltage read level for determining whether a value of each bit in a received word read out from the non-volatile memory is “0” or “1”. A difference between the number of bits which have value equals “0” and the number of bits which have value equals “1” in the code word depends on a code rate of the encoding. The controller obtains the threshold-voltage read level based on the code rate.

Abstract: According to one embodiment, a memory controller includes a first decoder that decodes a block product code read out from a non-volatile memory and calculates reliability information of each sub-block, and an error cancellation unit that detects a sub-block having many errors based on the reliability information, and performs EXOR operation of a codeword in a column direction including the detected sub-block and a codeword in a row direction including the detected sub-block, and performs decoding using a result of the EXOR operation.

Abstract: In accordance with at least some embodiments, a process for determining the safety of an elevator may be implemented to collect, by an acceleration sensor, an operational measurement of the elevator in operation, wherein the operational measurement includes a velocity measurement of the elevator. The process may be implemented to determine, by a processor, an operational status of the elevator by evaluating the operational measurement. The process may further be implemented to generate, by the processor, a warning signal when the operational status indicates that the elevator is operating abnormally.

Abstract: In accordance with at least some embodiments of the present disclosure, a process for determining the safety of an elevator is described. The process may be implemented to collect, by an acceleration sensor, an operational measurement of the elevator in operation, wherein the operational measurement comprises a velocity measurement of the elevator. The process may be implemented to determine, by a processor, an operational status of the elevator by evaluating the operational measurement. The process may further be implemented to generate, by the processor, a warning signal when the operational status indicates that the elevator is operating abnormally.

Abstract: This invention provides a composition comprising a recombinant adeno-associated virus 2/5 (rAAV2/5) which encodes consecutive amino acids 114-281 of the amino acid sequence of the extracellular domain of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). This invention also provides a pharmaceutical composition comprising such composition and a pharmaceutically acceptable carrier. This invention provides a method for treating lung cancer in a subject. The invention further provides a kit comprising a pharmaceutical composition comprising a composition comprising a recombinant adeno-associated virus 2/5 (rAAV2/5) which encodes consecutive amino acids 114-281 of the amino acid sequence of the extracellular domain of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and a pharmaceutically acceptable carrier, and instructions for use.

Abstract: This invention relates to novel propenone oxime ethers, methods of preparing them and pharmaceutical compositions containing them. The compounds have the formula: ##STR1## wherein R.sup.1 is H, or glucuronide;R.sup.2 and R.sup.3 are independently H or methyl;R.sup.4 is 0, or glucuronide, andn is 0 or 1, provided that when R.sup.1 is H, n is 1.

Abstract: Novel thermostable alkaline metalloprotease produced by Hyphomonas which is stabile under conditions of elevated pH. Also included are a method for its production, and compositions containing the metalloprotease useful for degrading proteinaceous materials.